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OBJECTIVE: An HPV/cancer epidemiology model has been
developed aiming to be succinct in structure and data input pro-
viding valid long-term HPV infection and cancer case predic-
tions, a ﬁrst step for estimating cost-effectiveness of new HPV
vaccines. METHOD: A lifetime Markov process model with one
year cycle length has been selected as basic matrix and is devel-
oped in Microsoft®Excel software. The model structure describes
the natural history of High-Risk HPV (HR-HPV) infections
through 9 health states: No-HPV; HR-HPV without lesions; low
and high grade Cervical Intraepithelial Neoplasia (CIN1 and
CIN23); persistent CIN23; CC; cured CC; CC death; and overall
death. A screening module (organized and/or opportunistic) sim-
ulates early detection and treatment of CIN lesions reducing their
progression to CC. Two types of data-sets for data-input are
created: related to the natural history of the disease (supposed
to be equivalent across countries and extracted from literature
or from expert opinion) and country-speciﬁc (HPV incidence,
death rate, screening practice, CIN and cancer speciﬁc treat-
ment). Outcome model validation is performed with French data
comparing model predicted cervical cancer incidence and mor-
tality rates with estimates from national cancer registries.
RESULTS: The model predicts 1.7 cases per 100,000 subjects in
20 to 24 age-group (1.3 observed); 21.3 cases in 40 to 44 age-
group (19.8 observed); 17.9 cases in 75 to 79 age-group (17.2
observed). Overall the model overestimates the CC cases with
only 5% (n = 3569 modeled cancer cases; 3387 observed for the
year 2000). CONCLUSION: Succinct model development is able
to replicate within 5% conﬁdence the CC incidence observed.
The model is a helpful tool for simulating economical conse-
quences of HPV vaccine in those countries with paucity of data
which doesn’t allow using the more complex models.
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TRASTUZUMAB USE FOR METASTATIC BREAST CANCER—IS
“MEDIAN TIME TO TREATMENT FAILURE” AN ACCURATE
PARAMETER FOR BUDGET IMPACT ANALYSIS?
Hammerman A, Klang SH, Liebermann N
Clalit Health Services,Tel-Aviv, Israel
OBJECTIVES: Budget Impact Analysis (BIA) preformed for new
and expensive anti-cancer drugs should rely on precise data
regarding the cost and amount of drug that would be utilized.
Besides epidemiology & required doses, BIA needs to take into
account the mean duration of treatment (DOT). In metastatic
cancer, patients are usually treated by each line until disease pro-
gression. When reporting phase III trials, not all patients have
failed treatment, and only “median time to treatment failure” is
available. Therefore, BIA would rely on the median rather than
the mean DOT. Five years after introducing Trastuzumab in the
Israeli national formulary, we evaluated whether the original BIA
based on a phase III trial, was accurate. METHODS: Clalit
Health Services’ computerized database was used to determine
Trastuzumab DOT in all patients that started treatment during
2000–2002. The mean & median DOT was compared to the
“median time to treatment failure” (5.8 months) in a phase III
trial. RESULTS: In year 2000, the median and average DOT
were 6.0 months and 9.9 months, respectively (n = 132) (patients
have received prior treatment with AC & T, as determined by
formulary criteria). In 2001 the median and average DOT were
9.0 and 13.6 months, respectively (n = 89) (criteria were
changed, and patients were only required to be pretreated with
AC). In 2002, the median DOT was 11.0 months and the mean
DOT was14.4 months (n = 71). CONCLUSIONS: In “real life”
patients, mean trastuzumab DOT for metastatic breast cancer
was 31–65% higher than the median DOT in the same patients.
Median DOT itself was up to 55% higher than reported in the
phase III trial. When performing BIA for treatments of metasta-
tic cancer, the estimation of the budget impact may be substan-
tially higher when using the mean rather the median value,
reported in phase III clinical trials.
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PRESCRIPTION MEDICATION COSTS TO PROSTATE CANCER
PATIENTS: SURVEY RESPONSES COMPARED TO AN
ADMINISTRATIVE REGISTER
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OBJECTIVES: Economic evaluations conducted from a societal
perspective may include estimates of out-of-pocket expenses.
Surveys and administrative registers offer two sources of out-of-
pocket cost data for use in economic evaluations. We highlight
potential problems in using questionnaires or administrative data
alone. METHODS: Data are obtained by surveys and from an
administrative register. Survey data include responses concerning
out-of-pocket expenditure on prescription medications from men
(N  1400) who have been diagnosed as having prostate cancer
prior to the 2004 survey. Register data concerning out-of-pocket
expenditure on physician-prescribed medications are available
for the survey population for pertinent time periods from the
Finnish Social Insurance Institution. Register data and question-
naire data are linked using unique personal identiﬁcation codes.
Statistical comparison of these sources of estimates is performed
using t-tests. RESULTS: The survey–based estimate of mean
out–of–pocket expenses in the previous 12 months is €297, the
corresponding ﬁgure from the administrative register is €259.
The listwise estimate of survey–based overestimation is €38 and
the difference between the two estimates of mean out–of–pocket
expenses are statistically signiﬁcant at the 5% level. We ﬁnd that,
performing imputation for unit and item non–response in the
survey database and for non–inclusion in the administrative reg-
ister, the survey–based estimate becomes 252€ and the regis-
ter–based estimate becomes €255—no longer a statistically
signiﬁcant difference. CONCLUSIONS: The problems of recall
error and non–response can complicate the estimation of out–
of–pocket expenditure using survey methodology. High–quality
public sector administrative registers can serve the information
needs of health economic evaluations. However, register–based
information can also be usefully supplemented by questionnaire
responses and vice versa.
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THE ECONOMIC VALUE OF INNOVATIVE TREATMENTS OVER
THE PRODUCT LIFE CYCLE: THE CASE OF TRASTUZUMAB
Garrison LP,Veenstra DL
University of Washington, Seattle, WA, USA
OBJECTIVES: Most pharmacoeconomic evaluations use indica-
tion-speciﬁc models based on clinical trial data projected over a
lifetime horizon for a typical patient. This study estimates the
incremental cost-utility ratio (ICUR) and the aggregate economic
value over the product life cycle considering multiple indications
using trastuzumab (H, Herceptin®) for both metastatic (MBC)
